+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers



Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers



Clinical Drug Investigation 18(2): 141-150



Objective: This study was performed to assess the tolerability of combined administration of reboxetine, a selective noradrenaline (norepinephrine) reuptake inhibitor, and fluoxetine, a selective serotonin reuptake inhibitor, relative to administration of each drug separately. Design: The following treatments were administered for 8 days according to a randomised, double-blind, placebo-controlled parallel design: (a) oral reboxetine 4mg twice daily, (b) oral fluoxetine 20mg once daily, or (c) oral reboxetine 4mg twice daily and fluoxetine 20mg once daily. Participants: Thirty healthy, nonsmoking volunteers (27 male, three female), aged between 20 and 55 years and within 15% of normal bodyweight were included in the study. Target Parameters: Plasma reboxetine enantiomers were quantified using HPLC-MS-MS. Fluoxetine and norfluoxetine concentrations were determined using high performance liquid chromatography. Pharmacokinetic parameters were compared by unpaired t-test. Clinical laboratory data were analysed as the change from baseline, and adverse events were tabulated by treatment. Vital sign and Digit Symbol Substitution Test (DSST) data were analysed by repeated measures analysis of variance. Results: The adverse event profiles were similar for combined reboxetine and fluoxetine relative to administration of each drug separately. Reboxetine significantly increased mean standing and supine heart rate versus baseline, whereas heart rate was not modified by fluoxetine. No statistically significant treatment effects were seen for DSST scores or oral temperature. The area under the plasma concentration-time curve from 0 to 12 hours for S,S(+) reboxetine was approximately 23% higher with fluoxetine coadministration than with reboxetine alone, but this effect, as well as effects on other pharmacokinetic parameters for either reboxetine enantiomer, was not statistically significant. In addition, no statistically significant effects of reboxetine on fluoxetine or norfluoxetine pharmacokinetics were observed. Conclusion: Combined administration of reboxetine and fluoxetine was well tolerated in healthy volunteers. These results suggest minimal clinical impact when these drugs are administered concomitantly to depressed patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010619951

Download citation: RISBibTeXText

DOI: 10.2165/00044011-199918020-00007


Related references

Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. Journal of Clinical Pharmacology 41(2): 217-223, 2001

Assessment of The Pharmacokinetic (PK), Pharmacodynamic (PD) Interaction Potential Between Posaconazole and Glipizide in Healthy Volunteers. Clinical Pharmacology & Therapeutics 73(2): P45-P45, 2003

Assessment of the pharmacokinetic , pharmacodynamic interaction potential between posaconazole and glipizide in healthy volunteers. Clinical Pharmacology & Therapeutics 73(2): P45, 2003

Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharmaceutics and Drug Disposition 27(6): 285-289, 2006

Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. Journal of Clinical Pharmacology 47(8): 978-990, 2007

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. European Journal of Clinical Pharmacology 69(4): 835-842, 2013

Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. Pharmacology 99(1-2): 84-88, 2017

The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers. Journal of Cardiovascular Pharmacology 18(Suppl. 11): S13-S17, 1991

A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 37, 2003

Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. Current Therapeutic Research Clinical and Experimental 71(6): 360-368, 2010

Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. British Journal of Clinical Pharmacology 83(10): 2225-2234, 2017

Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. Journal of Clinical Pharmacology 34(8): 837-841, 1994

Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic-Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers. Clinical Pharmacology and Therapeutics 102(1): 115-122, 2017

Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. Journal of Clinical Pharmacology 53(7): 738-745, 2013

Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. International Journal of Clinical Pharmacology and Therapeutics 49(12): 756-764, 2011